Eric Lefkofsky Helps Raise 80 Million Dollars To Help Cancer Paitents Find Better Treatment Options

Tempus Labs is a cancer data gathering technology company that is located in Chicago. Tempus uses RNA, DNA, and molecular data of patients to find the best way possible for them to treat a patient. They look deeper into what kinds of medicines are working for a patient but also they look into the age, the other diseases a patient might have, why a medicine works and why it doesn’t. This information is not at a doctor’s fingertips but Tempus is working as hard as they can to make this information open to doctors so together Tempus and a patients doctor can make a well thought out plan of how to treat patient’s cancer but also help people in the future who develop cancer by knowing things that happen frequently with certain people who have similarities.

Tempus Labs Co-Founder Eric Lefkofsky is very interested in using the technology Tempus has been provided with and finding similarities and differences between patients in treatment so they can find ways to fix treatment plans to meet a patient’s more specific needs in hopes that it will help them to not only be treated better but also rid them of that cancer that they have. His main goal in life is to enhance/ better the lives of humans so that they can live a full life.

Tempus Labs has raised 210 million dollars over time since they started up over two years ago and recently they just raised 80 million dollars so they can further their research in helping patients. Overall, With the amount of money, Tempus Labs is able to raise towards cancer research they can slowly but surely figure out how to help more and more people find the right treatment plans for them. They can also use the money they have raised to hire more employees to help them do this. They currently have a little over 4,000 employees but could always use more, right now they onboard about 30 new people a month but with more fund-raising, they could up their amount of employees hired by quite a few more people along with finding more research tactics and stuff.

To Read More Click Here

How Eric Lefkofsky’s Start-Up Company Is Changing Healthcare.

Eric Lefkofsky is the man behind the big data craze that is sweeping through the world of technology. Lefkofsky is making headlines out of Chicago’s busy tech sector with his new startup, Tempus. Tempus was co-founded by Lefkofsky back in 2015 and over the past three years, the company has continued to grow by leaps and bounds, with more than 30 new employees being added to the roster on a monthly basis. Tempus is seeking to provide a solution to the world of cancer care in the form of streamlined databases filled with patient care information. Tempus recently hit a financial milestone which makes it all the more likely that the company has some measure of success in their mission.

Tempus is seeking to funnel molecular data into a technological database that can be accessed by medical professionals and patients who want to stay informed regarding the cancer care treatment that they are undergoing. The goal here is simple and it is the bedrock by which Lefkofsky has been helping to build up his company. Lefkofsky wants to make information so accessible that healthcare professionals are able to discern patterns within treatment plans that can make their job easier and, in return, help to save lives.

One of the most recent reasons for optimism at Tempus comes by way of their newly minted Unicorn status. After another round of private investing, Tempus managed to cross the $210 million mark. Companies like T. Rowe Price Associates, Kinship Trust Co, New Enterprise Associates and Revolution Growth all combined to add another $80 million to Tempus’ bottom line. This recent allotment of donations helped to push Tempus’ evaluation to north of $1 billion. By reaching this number, Tempus was able to become one of the few Chicago-based startups that managed to earn the title of Unicorn status.

Lefkofsky has largely stayed focused on mission at hand but he hasn’t been shy when it comes to revealing optimism for the future of the Tempus project. Lefkofsky points out that Tempus is existing within a ‘paradigm shift’ that could be changing the expectations that patients and healthcare professionals have.

To Know More Click Here

Eric Lefkofsky and Tempus Labs – Individualizing Patient Care through Technology

Eric Lefkofsky is co-founder and CEO of Tempus Lab. Tempus Lab liaises with healthcare professionals in a variety of disciplines, including physicians and pharmaceutical companies, in a quest to expand the utility of data to improve the effectiveness of patient care and treatment. The focus of Tempus Labs is to expand treatment options for cancer patients and to that end data is collected, digitized, and stored in a searchable database so that critical information is available and accessible. Tempus Labs is a rarity in the world of business startups. Most startups fail within the first four years, but Tempus Labs is now a member of an elite “club” of startups. Tempus Labs is a “unicorn.”

“Unicorn” is a term coined by a venture capitalist named Aileen Lee to describe startups with a valuation of more than $1 billion. Tempus Labs, according to a recent Chicago Tribune article, soared into the ranks of unicorns with recent investments. Tempus Labs and Eric Lefkofsky received a recent investment of $80 million boosting investments to $210 million since 2015. With that infusion of investment dollars, the total valuation of Tempus Labs soared to $1.1 billion, hence the title “unicorn.”

Tempus Labs is thriving in the world of healthcare, and because of the strength of the company, they are increasing their employees by approximately 30 each month. Tempus Labs gathers and analyzes clinical data as well as data from the molecular level of patients receiving cancer treatments, to personalize treatment. This data is stored in an operating system developed by Tempus Labs, a system that enables the individualization of patient care through its “interactive analytical and machine learning platform.” The operating system makes data available in real time allowing physicians to make data-driven decisions that will benefit the lives of their patients.

Eric Lefkofsky and his wife Liz established a charitable foundation known as the Lefkofsky Family Foundation (LFF). Through their foundation, Mr. and Mrs. Lefkofsky fulfill the mission of Tempus Labs, which is to “enhance the quality of human life,” and they do that through their philanthropy. Their philanthropy extends into the areas of education, human rights, medicine, and arts and culture.

For More info: www.crunchbase.com/person/eric-lefkofsky

The Philanthropy Of Eric Lefkofsky

The Philanthropy of Eric Lefkofsky

Eric Lefkofsky is an entrepreneur and philanthropist. He earned his bachelor’s degree from the University of Michigan and earned a Juris Doctor degree from the University of Michigan Law School. He is a adjunct professor at the University of Chicago and a published author of the book Accelerated Disruption. He is the Chief Executive Officer co-founder of a technology company known as Tempus and the co-founder and the Chairman of Lightbark, an investment venture funding disruptive technologies. He is also the co-founder of Groupon. He is dedicated to battling cancer through technology and the advancement of science.

Tempus was established to eradicate cancer. This is being done in two ways: the ability to sequence the DNA of cancer patients and utilizing the immune system through targeted therapies that genetically match the patients DNA. They are proactively trying to understand why some patients respond to immunotherapy and others do not. Their team of over 150 immunologists, geneticists and biologists along with engineers and data scientists combine data science with computer technology to analyze tumor biopsies utilizing visuals generated by the computer and the integration of DNA and RNA information to machine learning.

A state of the art lab was built at Tempus to sequence DNA and RNA. This lab is highly robotic and annually sequences samples from over 50,000 patients. This work is completed in 2 to 3 weeks. This data is analyzed at the molecular level in order to understand the biological nature of a patient’s tumor and treatment is specifically tailored to target and fight the cancer.

The company has been partnering with various hospitals and medical centers to enhance their own biotechnological capabilities. They believe that it is important to have this cutting edge technology available to their doctors and physicians in order to provide improved medical services as an option to their patients.

To Learn More Click Here